A review of tigecycline

Journal of Chemotherapy

Volumn 20, Issue SUPPL. 1, 2008, Pages 3-11

  French, Gary L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Glycylcylines; Mode of action; Tetracyclines; Tigecycline

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CHLORAMPHENICOL; CHLORTETRACYCLINE; COLISTIN; DOXYCYCLINE; ERYTHROMYCIN; IMIPENEM; MACROLIDE; MINOCYCLINE; OXYTETRACYCLINE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TIGECYCLINE;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL GENE; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTIOUS DIARRHEA; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; OSTEOMYELITIS; PHARMACODYNAMICS; PHOTOSENSITIVITY; PHOTOTOXICITY; RECOMMENDED DRUG DOSE; REVIEW; SKIN INFECTION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 57749177153     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.supplement-1.3     Document Type: Review

References (86)

1. Chopra I. Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 2001; 65: 232-260.
2. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56: 20-51.
3. Paulsen IT, Brown MH. Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev 1996; 60: 575-608.
4. Bolhuis H, van Veen HW, Poolman B et al. Mechanisms of multidrug transporters. FEMS Microbiol Rev 1997; 21: 55-84.
5. Kumar A. Schweizer HP. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 2005; 57: 1486-1513.
6. Hooper DC. Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. Clin Infect Dis 2005; 40: 1811-1817.
7. Hillen W. Berens C. Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu Rev Microbiol 1994; 48: 345-369.
8. Levy SB (1984). Resistance to the tetracyclines. In Antimicrobial drug resistance. (Bryan, L. E., Ed). Academic Press, Orlando, Fl.
9. Okusu H, Ma D. Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol 1996; 178: 306-308.
10. Poole K, Krebes K, McNally C et al. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993; 175: 7363-7372.
11. Masuda N, Sakagawa E, Ohya S et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-3327.
12. Chuanchuen R, Beinlich K, Hoang TT et al. Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob Agents Chemother 2001; 45: 428-432.
13. Connell SR, Tracz DM, Nierhaus KH et al. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 2003; 47: 3675-3681.
14. Speer BS, Bedzyk L. Salyers AA. Evidence that a novel tetracycline resistance gene found on two Bacteroides transposons encodes an NADP-requiring oxidoreductase. J Bacteriol 1991; 173: 176-183.
15. Clewell DB, Flannagan SE. Jaworski DD. Unconstrained bacterial promiscuity: the Tn916-Tn1545 family of conjugative transposons. Trends Microbiol 1995; 3: 229-236.
16. Binet R. Maurelli AT. Fitness cost due to mutations in the 16S rRNA associated with spectinomycin resistance in Chlamydia psittaci 6BC. Antimicrob Agents Chemother 2005; 49: 4455-4464.
17. McOrist S. Obligate intracellular bacteria and antibiotic resistance. Trends Microbiol 2000; 8: 483-486.
18. Tally FT, Ellestad GA. Testa RT. Glycylcyclines: a new generation of tetracyclines. J Antimicrob Chemother 1995; 35: 449-452.
19. Sum PE, Lee VJ, Testa RT et al. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem. 1994; 37: 184-188.
20. Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorganic Med Chem Lett 1999; 9: 1459-1462.
21. Testa RT, Petersen PJ, Jacobus NV et al. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993; 37: 2270-2277.
22. Bauer G, Berens C, Projan SJ et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592-599.
23. Bergeron J, Ammirati M, Danley D et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996; 40: 2226-2228.
24. Rasmussen BA, Gluzman Y. Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother. 1994; 38: 1658-1660.
25. Barden TC, Buckwalter BL, Testa RT et al. "Glycylcyclines". 3.9-Aminodoxycyclinecarboxamides. J Med Chem 1994; 37: 3205-3211.
26. Orth P, Schnappinger D, Sum PE et al. Crystal structure of the tet repressor in complex with a novel tetracycline, 9-(N,N-dimethylglycylamido)- n-6-demethyl-6-deoxy-tetracycline. J Mol Biol 1999; 285: 455-461.
27. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005; 49: 791-793.
28. Dean CR, Visalli MA, Projan SJ et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-978.
29. (2006). Tigecycline - EUCAST clinical MIC breakpoints
30. (2006). Tygacil (tigecycline): package insert.
31. Petersen PJ, Bradford PA. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother 2005; 49: 3910-3918.
32. Bradford PA, Petersen PJ, Young M et al. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005; 49: 3903-3909.
33. Brown SD. Traczewski MM. Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbiol 2007; 45: 2173-2179.
34. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36.
35. Ruzin A, Visalli MA, Keeney D et al. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 2005; 49: 1017-1022.
36. Visalli MA, Murphy E, Projan SJ et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47: 665-669.
37. Boucher HW, Wennersten CB. Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against Gram-positive bacteria. Antimicrob Agents Chemother 2000; 44: 2225-2229.
38. Gales A, Jones R, Pfaller M. Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group. Int J Infect Dis 2000; 4.
39. Bradford PA. Tigecycline: a first in class glycylcycline. Clin Microiol News 2004; 26: 163-168.
40. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20: 219S-223S; discussion 224S-228S.
41. Betriu C, Rodriguez-Avial I, Sanchez BA et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother. 2002; 46: 892-895.
42. Betriu C, Rodriguez-Avial I, Sanchez BA et al. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002; 50: 758-759.
43. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001; 40: 173-177.
44. Edlund C, Nord CE. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000; 6: 159-163.
45. Goldstein EJC, Citron DM, Merriam CV et al. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000; 44: 2747-2751.
46. Henwood SJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-487.
47. Mercier R-C, Kennedy C. Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22: 1517-1523.
48. Milatovic D, Schmitz F-J, Verhoef J et al. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400-404.
49. Petersen PJ, Bradford PA, Weiss WJ et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595-2601.
50. Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-744.
51. Rhomberg PR, Jones RN. In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn Microbiol Infect Dis 2002; 42: 145-147.
52. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis, Int J Antimicrob Agents 2000; 16: 61-63.
53. Cercenado E, Cercenado S, Gomez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003; 52: 138-139.
54. Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1875-1881.
55. Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1867-1874.
56. Wallace Jr RJ, Brown-Elliot BA, Crist CJ et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of Nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-3167.
57. Hoellman DB, Pankuch GA, Jacobs MR et al. Antipneumococcal activity of GAR 936, a new glycylcycline, compared to those of nine other agents against penicillin susceptible and resistant pneumococci. Antimicrob Agents Chemother 2000; 44: 1085-1088.
58. Cercenado E, Cercenado S, Bouza E. in vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates. Antimicrob Agents Chemother 2003; 47: 2644-2645.
59. Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist 2007; 13: 1-6.
60. Navon-Venezia S, Leavitt A. Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 772-774.
61. Pachón-Ibáñez ME, Jiménez-Mejías ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-4481.
62. Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58: 1099-1100.
63. Coelho JM, Turton JF, Kaufmann ME et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44: 3623-3627.
64. Lolans K, Rice TW, Munoz-Price LS et al. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50: 2941-2945.
65. Bozdogan B, Esel D, Whitener C et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52: 864-868.
66. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45: 2604-2608.
67. Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 2003; 47: 533-540.
68. Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother 2007; 59: 1001-1004.
69. Keeney D, Ruzin A, McAleese F et al. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 2008; 61: 46-53.
70. Hirata T, Saito A, Nishino K et al. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004; 48: 2179-2184.
71. Peleg AY, Potoski BA, Rea R et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59: 128-131.
72. Reid GE, Grim SA, Aldeza CA et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-1201.
73. Meagher AK, Ambrose PG, Grasela TH et al. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52: 165-171.
74. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-229.
75. Hoffmann M, DeMaio W, Jordan RA et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007; 35: 1543-1553.
76. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008; 62 Suppl 1: i11-16.
77. van Ogtrop ML, Andes D, Stamstad TJ et al. in vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother. 2000; 44: 943-949.
78. Conte JE, Jr., Golden JA, Kelly MG et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-529.
79. Meagher AK, Passarell JA, Cirincione BB et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007; 51: 1939-1945.
80. Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-367.
81. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-353.
82. Baines SD, Saxton K, Freeman J et al. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006; 58: 1062-1065.
83. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50: 3375-3380.
84. Wilcox MH. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin Microbiol Infect 2007; 13: 949-952.
85. Bergstrom CT, Lo M.Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 2004; 101: 13285-13290.
86. Ji AJ, Saunders JP, Wadgaonkar ND et al. A novel antibiotic bone assay by liquid chromatography/tandem mass spectrometry for quantitation of tigecycline in rat bone. J Pharm Biomed Anal 2007; 44: 970-979.